Novel antidepressant, a selective inhibitor of MAO-A.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 390.54. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.56 mL||12.8 mL||25.61 mL|
|5 mM||0.51 mL||2.56 mL||5.12 mL|
|10 mM||0.26 mL||1.28 mL||2.56 mL|
|50 mM||0.05 mL||0.26 mL||0.51 mL|
References are publications that support the products' biological activity.
Bos et al (1995) Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch.Pharm. (Wenheim) 328 619 PMID: 7492268
Korshunov et al (2000) Hemodynamic effects of tetrindol in alert normotensive mice and rats after blockade of nitric oxide synthesis. Bull.Exp.Biol.Med. 130 777 PMID: 11177242
Medvedev et al (1994) Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem.Pharmacol. 47 303 PMID: 8304974
If you know of a relevant reference for Tetrindole mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Tetrindole mesylate, supplier, MAO-A, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, Monoamine, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, Monoamine, Oxidase, Tocris Bioscience
Citations for Tetrindole mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Tetrindole mesylate. Do you know of a great paper that uses Tetrindole mesylate from Tocris? If so please let us know.
Tetrindole mesylate Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.